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Istanbul, TurkeyAbstractThe present study was designed to determine the seroprevalence of hepatitis B and C virus (HBV, HCV) infections and risk factors in the
Turkish general population. Participants were enrolled from urban and rural areas of the predetermined 23 EUROSTAT NUTS 2 region. A
two-stage stratiﬁed sampling method was used to select participants from these regions (n = 5460; 50.9% females; mean (SD) age: 40.8 (14.7)
years). Sociodemographics, clinical characteristics and risk factors were recorded at home visits. The seropositivity rates for hepatitis B
surface antigen (HBsAg), anti-HCV, anti-HBs and anti-HBc total were 4.0%, 1.0%, 31.9% and 30.6%, respectively. Among HBsAg-positive
cases, 94.5% were anti-HBe-positive, 70.2% were HBV-DNA-positive and 2.8% were anti-HDV total positive; 99.1% of HBV infections
were of genotype D. Close contact with a hepatitis patient (OR 3.24; 95% CI 2.25–4.66; p < 0.001), living in the southeastern region
(OR 2.74; 95% CI 1.7–4.45; p < 0.001), male gender (OR 1.77; 95% CI 1.28–2.46; p < 0.001), being married (OR 1.62; 95% CI
1.02–2.57; p 0.038), educational level less than high school (OR 1.53; 95% CI 1.04–2.26; p 0.03), orodental interventions (OR 1.54; 95%
CI 1.01–2.35; p 0.047) and a history of non-disposable syringe use (OR 1.4; 95% CI 1.01–1.96; p 0.045) were signiﬁcant determinants of
HBsAg positivity. Age 50 years (OR 2; 95% CI 1.09–4.3; p 0.026) was the only signiﬁcant predictor of anti-HCV positivity. In
conclusion, our ﬁndings revealed an HBsAg positivity in 4% and anti-HCV positivity in 1% of the adult population and at least one-third
of the population has been exposed to HBV infection in Turkey.
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hotmail.comIntroductionAn estimated 350–400 million people with chronic hepatitis B
virus (HBV) infection and 170 million people with chronic hepa-
titis C virus (HCV) infection have been reported worldwide [1,2].Microbiol Infect 2015; 21: 1020–1026
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.028The prevalence of HBV infection varies widely by
geographic region [3], ranging from 0.1% to 20% in different
parts of the world [4], and from 2% to 8% in countries with
intermediate endemicity for hepatitis B infection including
Turkey [5,6].
Based mainly on studies in blood donors, the overall prev-
alence of chronic HBV infection has been reported to range
from 4% to 5% [7] in Turkey with considerable regional dif-
ferences [8] and a decline to 2% has been evident in recent
years [10]. The Turkish Ministry of Health declared the inci-
dence of hepatitis B infection to be 8.26 by 2002 and 4.2 by
2010 per 100 000 people [9]. A recent meta-analysis on viral
hepatitis in Turkey reported 4115 new cases/year with aious Diseases. Published by Elsevier Ltd. All rights reserved
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were associated with a morbidity rate of 3.79/100 000 in 2011
[10]. Signiﬁcant geographic and temporal differences were
noted in the epidemiology of HCV infection in Europe, with an
overall prevalence between 0.1% and 1% in northern Europe,
0.2% and 1.2% in Central Europe and 2.5% and 3.5% in southern
Europe [11].
Although epidemiological data on the general population are
limited in Eastern European countries, a high prevalence of
infection was documented among blood donors (0.9–5%),
healthcare workers (1–10%) and high-risk groups (i.e. 50–92%
in people with haemophilia) [11].
There is no national screening or reporting system for HCV
in Turkey, and the epidemiological data are derived mainly from
local studies [7,12–14] indicating anti-HCV positivity from 0.4%
to 1.5% in community-based studies, from 0.19% to 0.68% in
blood donors and from 2.2% to 2.4% in patients during routine
outpatient visits. The current best estimate for the prevalence
was reported to be approximately 1% [1].
As most of the studies on the epidemiology of HBV and HCV
infections in Turkey were conducted in blood donors and risk
groups and limited nationwide data are available in the general
population [7,8,12,15–19], the present population-based, large-
scale ﬁeld study was designed to determine seroprevalence of
HBV, HCV and hepatitis delta virus (HDV) infections in relation
to risk factors for increased seropositivity in the Turkish gen-
eral population.Materials and methodsStudy population
In the present ﬁeldwork, TURHEP Study, 5533 volunteers were
screened through home visits in 2009–2010 living in urban and
rural areas of 23 cities located in EUROSTATNUTS 2 regions of
Turkey and determined based on two-stage stratiﬁed sampling
method. The participants were selected according to a ran-
domized sampling method of the Statistics Institute of Turkey.
Participants’ sociodemographic features, anthropometrics,
medical history, concomitant medications and presence of risk
factors were recorded and blood samples were collected for
serum HBV, HDV, HCV markers, and alanine transaminase
(ALT) and aspartate transaminase (AST) were measured.
The inclusion criteria were, being 18 years of age, residing
in predetermined locations and volunteering to participate.
People who were visitors, lacked cognitive ability to respond to
study questions, or refused to provide contact details were
excluded from the study.
Before data collection, written informed consent was ob-
tained from each participant following a detailed explanation ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anthe objectives and protocol of the study, which was conducted
in accordance with the ethical principles stated in the Decla-
ration of Helsinki and approved by the Ministry of Health Pri-
mary Health Care Ethics Committee.
Blood tests and determination of risk factors
Blood samples (8–10 mL) were taken from all individuals for
serological and biochemical tests including hepatitis B surface
antigen (HBsAg), anti-HBs, hepatitis B core antibody (anti-HBc)
total, anti-HCV, hepatitis B e antigen (HBeAg), anti-HBe, HBV-
DNA, anti-HDV, ALT and AST measurements. Serum samples
were transmitted to the central laboratory under cold chain
with barcode labelling to be analysed.
Data on risk factors for HBsAg and anti-HCV positivity
including close contact with a hepatitis patient, geographical
region, gender, marital status, educational level, orodental in-
terventions, previous use of non-disposable syringe, circumci-
sion, unsafe sexual practices, intravenous drug use, blood
transfusion, surgery, piercing/tattoo/acupuncture and dialysis
were recorded on data collection forms by the physician using a
face-to-face interview method.
Serological and molecular assays
Serological tests were performed by Cobas Roche Diagnostics
using an electrochemiluminescence immunological assay. The
extraction procedure was performed by QIA symphony (Qia-
gen, Hilden, Germany) automated extraction system. HBV-
DNA quantiﬁcation by real-time PCR was performed in a
combination of Artus HBV RG PCR Kit (Artus™ GmbH,
Hamburg Germany) and the real-time PCR instrument, Rotor-
Gene Q (Qiagen). The analytical detection limit of HBV DNA is
10 IU/mL (linear range: 10–20 000 000 IU/mL).
Statistical analysis
At least 5000 volunteers were planned to be included in the
TURHEP study based on representation of hepatitis C in the
study sample with an expected prevalence of 0.8% and accuracy
0.2%. The statistical analysis included 5460 participants with
data available on seroprevalence and risk factors for HBV and
HBC infection.
Statistical analysis was performed using computer software
STATA version 11.0 (StataCorp. 2013. Stata Statistical Software:
Release 13. College Station, TX: StataCorp LP). Chi-square test
was used for the comparison of categorical data, and Student’s t
test was used for numeric variables. One sample Z-test was
used for the comparison of regional versus overall HBsAg
positivity. Logistic regression was used for multivariate analysis
to determine the predictors of HBsAg positivity and anti-HCV
positivity. The potential risk factors for HBsAg positivity and
anti-HCV positivity were included in the regression model.d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1020–1026
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and OR (95% CI), where appropriate. A p value < 0.05 was
considered statistically signiﬁcant.ResultsSociodemographic features and medical history
Mean (SD) age of the participants was 40.8 (14.7) years; 50.9%
were women; mostly aged <50 years, at least primary school
graduates, married and from urban areas (Table 1).
The HBsAg-positive and anti-HCV-positive participants were
older than the HBsAg-negative and anti-HCV-negative partici-
pants (p 0.019 and p < 0.001, respectively). Among HBsAg pos-
itive participants, males, those with lower educational status and
married participants were signiﬁcantly more common (Table 1).
Past history of infective jaundice was conﬁrmed by 7.6%
(n = 414) of the participants; but the type of infection was
known only by 42.0% (n = 174) and identiﬁed as HBV by 47.7%
(n = 83) and as HCV by 5.1% (n = 9) of these participants.
Among people recalling their previous immunization, 4.7
(n = 255) and 10.7% (n = 586) were vaccinated for hepatitis A
and B, respectively.
Although a limited number of men could give information
about their circumcision experience; the frequency of HBsAg
positivity was signiﬁcantly higher among those circumcised by a
barber (11/99; 11%; p 0.006), compared to those circumcised
by a circumciser (9/151; 6.0%; p 0.647), at a health centre (6/
116; 5.2%; p 1.000) and by a health ofﬁcer (29/720; 4%; p
0.072).TABLE 1. Sociodemographics of all participants according to HBsA
HBsAg (+)
n [ 218
HBsAg (−)
n [ 5242 p
Age (years), mean (SD) 42.8 (13.8) 40.7 (14.5) 0.019
Age group (years), n (%)
18–29 42 (19.3) 1445 (27.3) 0.059
30–39 54 (24.8) 1323 (25.4)
40–49 55 (25.3) 1080 (20.7)
50–59 41 (18.8) 706 (13.5)
60–69 14 (6.4) 400 (7.6)
70 11 (5.0) 247 (4.7)
Gender, n (%)
Female 89 (40.8) 2692 (51.3) 0.002
Male 129 (59.1) 2550 (48.6)
Educational status, n (%)
Less than high school 167 (76.6) 3647 (69.6) 0.027
High school or over 51 (23.4) 1594 (30.4)
High-risk profession, n (%) n = 218 n = 5241
Healthcare workers 3 (1.4) 242 (4.6) 0.024
Marital status, n (%)
Married 183 (84.0) 3979 (75.9) 0.006
Single (unmarried, widow(er)
and divorced)
35 (16.0) 1263 (24.1)
Place of residence, n (%)
Urban 147 (76.2) 3603 (75.0) 0.710
Rural 46 (23.8) 1202 (25.0)
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
aNumber with available data.
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The overall HBsAg seropositivity was 4% (218/5460); whereas
there was signiﬁcant variability among geographic regions
(p < 0.004): Aegean 2.3% (16/701; p 0.021 versus all regions),
Black Sea 6.1% (18/294; p 0.062), Central Anatolia 4.3% (56/
1301; p 0.566), Eastern Anatolia 3.4% (7/207; p 0.653), Mar-
mara 3.8% (86/2258; p 0.655), Mediterranean 3.1% (12/383; p
0.390) and Southeastern Anatolia 7.3% (23/316; p 0.003).
Anti-HCV seropositivity was detected in 1% (52/5460) of all
participants. Of 113 HBV-positive cases with genotype analysis,
99.1% were of genotype D. Among HCV-positive participants
92.1% were of genotype 1b.
In addition, HBsAg positivity was accompanied by anti-HDV
positivity in 2.8% and by anti-HCV positivity in 0.9%. Among
HBsAg-positive cases 94.5% were anti-HBe-positive and 4.1%
were HBeAg-positive (Table 2). HBV-DNA level was non-
detectable in 48 (22.0%), <2000 IU/mL in 88 (40.4%),
2000–20 000 IU/mL in 39 (17.9%) and >20 000 IU/mL in 43
(19.7%) of 218 HBsAg-positive participants.
Anti-HBs positivity was identiﬁed in 31.9% and anti-HBc
positivity in 30.6% of participants; whereas anti-HBs positivity
was accompanied with anti-HBc positivity in 22.0% and isolated
anti-HBc positivity was evident in 4.6% of all participants
(Table 2). None of these participants was HBV-DNA positive.
Risk factors for hepatitis B
Logistic regression analysis revealed that close contact with a
hepatitis patient, living in the southeastern region, male
gender, being married, educational level less than high school,
orodental interventions and past use of non-disposableg and anti-HCV positivity
Anti-HCV (+)
n [ 52
Anti-HCV (−)
n [ 5371 p
All participantsa
n [ 5460
48.5 (16.0) 41.0 (15.0) <0.001 40.8 (14.7)
7 (13.4) 1483(28) 0.004 1490 (27.3)
11 (21.0) 1364 (25) 1375 (25.5)
9 (17.0) 1127 (21) 1136 (21.0)
10 (19.0) 738 (14) 748 (13.9)
9 (17.0) 405 (7.5) 414 (7.6)
6 (12.0) 242 (5.0) 248 (4.7)
33 (63.4) 2750 (51) 0.070 2783 (51.0)
19 (36.5) 2658 (49) 2677 (49.0)
43 (83.0) 3771 (70.0) 0.043 3814 (70.0)
9 (17.0) 1636 (30.0) 1645 (30.1)
n = 5459
4 (8.0) 241 (4.6) 0.265 245 (4.5)
39 (75.0) 4123 (76.0) 0.838 4162 (76.2)
13 (25.0) 1285 (24.0) 1298 (23.8)
38 (73.0) 3949 (73.0) 0.989 3987 (75.0)
14 (27.0) 1461 (27.0) 1475 (25.0)
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1020–1026
TABLE 4. Risk factors for anti-hepatitis C virus positivity
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
Age 50 2.5 1.48–4.43 0.001 2 1.09–4.3 0.026
Close contact with
hepatitis patient
1.8 0.86–4.06 0.109 1.9 0.86–4.3 0.109
Living in southeastern
part (versus other
regions)
2.1 0.9–5.06 0.081 1.4 0.42–4.73 0.565
Male gender 0.6 0.33–1.05 0.073 0.6 0.28–1.4 0.258
Being married (versus
single: unmarried,
widow/widower,
divorced)
0.93 0.49–1.75 0.838 1.1 0.5–2.48 0.783
Educational level less
than high school
2 1.01–4.26 0.047 1.3 0.56–2.94 0.552
Orodental interventions 1.5 0.72–3.08 0.275 1.3 0.54–2.97 0.575
Use of non-disposable
syringe
1.7 0.35–19.51 0.071 1.07 0.53–2.15 0.849
Unsafe sexual practices 0.75 0.28–2.01 0.572 0.5 0.08–3.04 0.459
Transfusion of blood and
blood products
2.2 1.14–4.39 0.018 1.3 0.55–3.16 0.519
Surgery 1.5 0.86–2.63 0.147 1.1 0.57–2.18 0.743
Piercing/Tattoo and/or
acupuncture
1.5 0.83–2.61 0.175 1.1 0.55–2.49 0.667
Dialysis (0%) (0.2%) 0.768
TABLE 2. Serological ﬁndings in relation to HBsAg and Anti-
HBs positivity
n % N
HBsAg (+) 218 4.0 5460
+ HBeAg (+) 9 4.1 218
+ Anti-HBe (+) 206 94.5 218
+ HBV-DNA (+) 153 70.2 218
+ HBV-DNA (+) + ALT >1.5 UNL 6 2.8 218
+ HBV-DNA (−) 65 29.8 218
+ HBV-DNA (−) + ALT >1.5 UNL 1 0.4 218
+ Anti-HCV (+) 2 0.9 218
+ Anti-HDV (+) 6 2.8 218
Anti-HBs (+) 1746 31.9 5460
Anti-HBc (+) 1670 30.6 5460
Anti-HBs (+) + Anti-HBc (+) 1212 22.0 5460
Anti-HBs (+) + Anti-HBc (−) 463 8.4 5460
Isolated Anti-HBc (+) 251 4.6 5459
ALT, alanine transaminase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; UNL, upper normal limit.
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(Table 3).
Risk factors for hepatitis C
Logistic regression analysis revealed that age >50 years was the
signiﬁcant predictor of anti-HCV positivity (Table 4). Educa-
tional level less than high school and transfusion of blood and
blood products were signiﬁcantly more frequent among anti-
HCV-positive participants in the univariate analysis, whereas
they were not conﬁrmed to have a signiﬁcant impact on anti-
HCV positivity in the multivariate analysis, probably because
of the small number of such participants (Table 4).DiscussionThis is the ﬁrst and largest population-based cross-sectional
screening on seroprevalence and risk factors associated withTABLE 3. Risk factors for hepatitis B surface antigen positivity
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Age 50 1.2 0.91–1.64 0.173 1.02 0.71–1.45 0.916
Close contact with
hepatitis patient
1.82 1.53–2.17 <0.001 3.24 2.25–4.66 <0.001
Living in southeastern
part (versus other
regions)
1.99 1.27–3.12 0.002 2.74 1.7–4.45 <0.001
Male gender 1.53 1.16–2.01 0.002 1.77 1.28–2.46 0.001
Being married (versus
single/unmarried,
widow/widower,
divorced)
1.66 1.14–2.39 0.007 1.62 1.02–2.57 0.038
Educational level less
than high school
1.43 1.04–1.96 0.028 1.53 1.04–2.26 0.03
Orodental interventions 1.68 1.15–2.44 0.006 1.54 1.01–2.35 0.047
Use of non-disposable
syringe
1.71 1.29–2.26 <0.001 1.4 1.01–1.96 0.045
Unsafe sexual practices 1.94 1.23–3.04 0.004 1.17 0.78–1.74 0.438
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anviral hepatitis in Turkey. Our ﬁndings of HBsAg (4.0%) and anti-
HBs (31.9%) seroprevalence fall within the ranges provided for
countries with an intermediate endemic proﬁle [4,20] and are
in agreement with past studies on epidemiology of hepatitis in
Turkey, which indicated an overall prevalence of chronic HBV
infection of 4–10% (3.5% in the western and 7% in the eastern
regions), and of anti-HBs positivity of 20.6–52.3%
[7,10,14,15,19,21,22]. This regional difference in HBV positivity,
which is not observed in HCV infection, re-emphasizes the role
of close contact and intrafamilial transmission in areas with
crowded families and poor hygienic conditions in HBV
seroprevalence.
HBsAg positivity was higher in the middle-aged compared
with younger and older participants in our series. An 11-year
retrospective analysis of epidemiological trends in HBV in-
fections after the implementation of the nationwide vaccination
programme in Turkey revealed a stable anti-HBs incidence
(43.6%) and intermediate HBsAg seroprevalence of 6.0% with a
signiﬁcant decrease from 12.3% in 2000 to 5.0% in 2010 [19].
Despite the inclusion of older participants and the fact that only
10.7% of our participants recalled having been vaccinated
against hepatitis B, HBsAg seropositivity prevalence (4.0%) was
lower than previous reports [15,20,23]. Since 1998, HBV vac-
cine has been administered free of charge to all newborns.
Furthermore, a catch up vaccination is offered for non-
vaccinated children at primary school; and risk groups are
also being vaccinated. The immunization coverage for HBV was
97% by the year 2013 [24]. Since 2012, hepatitis A virus vaccine
has been included in the newborn immunization programme.d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1020–1026
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the introduction of disposable syringes into clinical practice
since late 1980s and implementation of more efﬁcient preven-
tive measures in the community within the scope of the Hep-
atitis B Control Programme in the country [22].
Likewise, a recent systematic review evaluating 129 studies
published between 1999 and 2009 revealed that the estimated
overall population prevalence was 4.57 (95% CI 3.58–5.76)
with an estimated total number of HBV-positive cases of about
3.3 million [8].
Another recent meta-analysis reported that globally the
prevalence and number of people with anti-HCV has increased
from 2.3% to 2.8% between 1990 and 2005 [25]. Overall,
Turkey has a low prevalence of HCV infection. This might be
related to the early introduction of screening of blood donors
and the low rate of intravenous drug use in Turkey. Our ﬁnding
of anti-HCV positivity (1%) seems in accordance with the data
from community-based studies in Turkey (0.4–1.5%)
[10,14,18]. In a previous epidemiological study, anti-HCV was
detected in 21 (1.5%) of 1374 persons and was more common
in residents >54 years of age [14]. Data from past studies on
risk factors for HCV infections in Turkey revealed that a history
of blood transfusion and nosocomial risk factors accounted for
the majority of HCV cases, while intravenous drug use was
reported in a small number of HCV cases (4% or less)
[13,16,26,27]. Likewise, sexual transmission and mother-to-
child transmission were low in Turkey [28,29]. The use of
non-disposable medical devices and unsafe surgical in-
terventions may have more impact on HCV seroprevalence
than intravenous drug use in our group.
Identiﬁcation of isolated anti-HBc positivity in 4.6% of the
overall study population is compatible with the previously re-
ported range of 3–5% for isolated anti-HBc positivity in Turkey
[30]. This may indicate the likelihood of occult chronic hepatitis
infection in these participants [31]; however, in none of these
anti HBc-positive cases was HBV DNA positive.
Data from retrospective analysis of HBV-related epidemio-
logical trends in Turkey revealed anti-HBe-positive infections to
be more frequent than HBeAg-positive infections (77.1% versus
18.5%) [19]. Only 30–35% of patients were HBeAg positive in
recent studies [15,32]. The fact that 94.5% of HBsAg-positive
participants in our study were anti-HBe positive re-
emphasized the role of mutant HBV infection in our region
[33].
Overall, anti-HDV total seropositivity was reported to range
between 2.9% and 33%, along with rates of 0–11.2% in
asymptomatic HBsAg carriers and 6.8–53.4% in patients with
chronic hepatitis [34–37]. Given the detection of anti-HDV
positivity in 0.1% of the overall study population and in 2.8%
of HBsAg-positive participants, our ﬁndings conﬁrm a high rateClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectof HDV infection compared with other countries, although a
recent reduction in HDV prevalence has been reported in
Spain, Taiwan and Turkey in the past three decades [35–39].
Regarding the risk factors, male gender, lower educational
level, being married, living in the southeastern region, close
contact with a hepatitis patient, orodental interventions and
previous use of non-disposable syringes were indicated as the
signiﬁcant independent determinants of HBsAg positivity; the
only risk factor associated with increased HCV prevalence was
age >50 years in our cohort. This different pattern between the
two viruses could be explained by a potential survival
phenomenon.
The association between male gender and increased HBsAg
positivity in our study may be linked to the fact that males tend
to have less seroconversion and more progression to chro-
nicity, easier access to medical care and more contact with the
infection at their work or social life [40].
Another regional factor of interest is the custom of
circumcision. As the majority of the inhabitants are Muslims and
all Muslim men have been circumcised before reaching puberty
[41] the higher HBsAg positivity among male participants who
were circumcised by a barber in the past compared with those
circumcised by health professionals in our study population may
reﬂect the role of circumcision method as a risk factor for HBV
transmission.
The identiﬁcation of orodental practices as an independent
determinant of increased HBsAg positivity in our study popu-
lation is compatible with viral hepatitis being considered an
important hazard in dental practice with risks of patient-to-
patient and patient-to-doctor transmission [42].
In conclusion, the ﬁndings of this ﬁrst population-based study
in Turkey with respect to the epidemiology of HBV and HCV
revealed HBsAg positivity in 4%, anti-HCV positivity in 1% and
anti-HDV positivity in 2.8% of HBsAg-positive individuals. Male
gender, lower educational level, being married, living in the
southeastern region, close contact with a hepatitis patient and
orodental interventions were identiﬁed as signiﬁcant indepen-
dent determinants of increased HBsAg positivity. Age 50
years was the only predictor of increased anti-HCV
seroprevalence.
Prospective and long-term studies in younger and larger
cohorts are needed to see the inﬂuence of the national vacci-
nation programme and public awareness campaigns on the
epidemiology of hepatitis B and C as well as morbidity and
mortality related to their long-term complications in society.
Due to a successful vaccination programme since 1998 HBV
incidence has declined in younger age groups. However, im-
munization of risk groups and awareness campaigns for viral
hepatitis still wait for more active and efﬁcient organization by
the authorities and related societies in the country.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1020–1026
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